Leishmaniasis Clinical Trial
Official title:
A Randomized, Double-blind, Placebo-controlled, First Time in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single (in Both Fed and Fasted States) Doses of GSK3494245 in Healthy Participants
This is a Phase 1, double-blind, randomized, placebo-controlled, first time in human (FTIH) study to assess the safety, tolerability and PK of a single dose of GSK3494245. The study will consist of 3 cohorts, conducted in a sequential manner. Cohorts 1 and 2 will consist of a single ascending dose (SAD), crossover design where each participant will receive a maximum of 3 ascending oral doses of GSK3494245 and 1 placebo dose under fasted conditions. At each dose level, GSK3494245 and placebo will be administered in a 3:1 ratio, within each period, according to the randomization schedule in a blinded manner. Cohort 3 will comprise of a 2-way crossover which includes 1 dosing regimen under fasted then fed conditions and 1 regimen under fed then fasted conditions in a 1:1 ratio. The fed conditions will investigate the effect of safety, tolerability and PK of a single dose of GSK3494245 following food administration.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
Completed |
NCT00004755 -
Allopurinol, Glucantime, or Allopurinol/Glucantime for Cutaneous Leishmaniasis in Brazil
|
Phase 2 | |
Completed |
NCT00657618 -
Use of Sodium Stibogluconate as a Treatment for Leishmaniasis
|
Phase 1/Phase 2 | |
Completed |
NCT04512742 -
A Clinical Study to Develop a Controlled Human Infection Model Using Leishmania Major-infected Sand Flies
|
N/A | |
Recruiting |
NCT00344188 -
Diagnosis and Treatment of Leishmania Infections
|
||
Active, not recruiting |
NCT03009422 -
Fractional CO2 Laser With Topical Pentostam Treatment for Cutaneous Leishmaniasis.
|
N/A | |
Recruiting |
NCT05449717 -
Incidence of Relapse and Post-Kala-Azar Dermal Leishmaniasis in South Sudan
|
||
Recruiting |
NCT06307171 -
Human Leishmaniasis: Antigen Recognition Pattern and Study of New Potential Biomarkers
|
N/A | |
Completed |
NCT01751048 -
LEISH-F3 + GLA-SE and the LEISH-F3 + MPL-SE Vaccine
|
Phase 1 | |
Terminated |
NCT06124144 -
Safety and Drug Absorption of Orally Administered Oleylphosphocholine (OlPC) in Healthy Adults
|
Phase 1 | |
Completed |
NCT00662012 -
Sodium Stibogluconate Treatment of Leishmaniasis
|
Phase 2 | |
Completed |
NCT03993093 -
Prevalence of HIV +ve Cases With AIDS Defining Opportunistic Infections Among ART Naive Patients Attending ART Centre
|
||
Recruiting |
NCT03784248 -
Mediterranean Visceral Leishmaniasis With Leishmania Infantum
|
||
Withdrawn |
NCT02429505 -
Treatment of Leishmaniasis With Impavido® (Miltefosine): Higher-Weight Patient Registry
|
||
Completed |
NCT01377974 -
Clinical Trial of Miltefosine to Treat Mucosal Leishmaniasis
|
Phase 2 | |
Completed |
NCT02656797 -
Topical Liposomal Amphotericin B Gel Treatment for Cutaneous Leishmaniasis
|
Phase 2 | |
Completed |
NCT01484548 -
Phase 1 LEISH-F3 Vaccine Trial in Healthy Adult Volunteers
|
Phase 1 | |
Completed |
NCT01300975 -
Intralesional Antimony for Bolivian Cutaneous Leishmaniasis
|
Phase 2 | |
Completed |
NCT03294161 -
Fourth-generation Immucillin Derivative DI4G Associated Therapy in Cutaneous Leishmaniasis
|
Phase 2 | |
Completed |
NCT00401557 -
Mechanisms Relating to the Distinct in Vitro Susceptibility of Human Macrophages to L. Viannia Infection
|